{"pageContent": "1\n EUPROMS (Europa Uomo Patient Reported Outcome Study)\nEUPROMS \nEuropa Uomo\u2019s study on quality of life  \nafter prostate cancer treatment\nSUMMARY OF FINDINGSEUPROMS (Europa Uomo Patient Reported Outcome Study) 3 2\n EUPROMS (Europa Uomo Patient Reported Outcome Study)Contents\nEUPROMS (the Europa Uomo\nPatient Reported Outcome\nStudy) is the first ever prostate\ncancer quality of life survey\nconducted by patients for\npatients.\nAbout EUROPROMS  4 \n About the questionnaire 4 \n Geographical response 5 \n About the respondents 5 \n About the analysis 9 \n Reporting the study results 9 \n How we hope the results will be used 9 \nEUROPROMS findings  10 \n\t 1.\tGeneral\tfindings\tabout\tquality\tof\tlife\t 11 \n\t 2.\tFindings\tabout\tdiscomfort,\ttiredness\tand\tinsomnia\t 12  \n 3. Findings about mental health 14 \n\t 4.\tFindings\tabout\tsexual\tfunction\t 17 \n 5. Findings about urinary incontinence 21 \nKey messages from EUPROMS  25  \nFurther\tinformation\t 28 \nLinks  30 EUPROMS (Europa Uomo Patient Reported Outcome Study) 5 4\n EUPROMS (Europa Uomo Patient Reported Outcome Study)The EUPROMS study (Europa Uomo Patient Reported Outcome \nStudy), which reported in 2020, is the first ever prostate cancer quality \nof life survey conducted by patients for patients. This booklet, written \nby Andr\u00e9 Deschamps, Chairman of Europa Uomo, and health writer \nSimon Crompton, is a non-academic overview of its findings.\nEuropa\tUomo\t(Italian\tfor\tEurope\tman)\tis\ta\tEuropean\tadvocacy\tmovement\t\nrepresenting\t27\tprostate\tpatients\u2019\tgroups\tin\tcountries\tacross\tEurope.\nQuality\tof\tlife\tfor\tmen\twith\tprostate\tcancer\tis\tintrinsic\tto\tall\tEuropa\tUomo\u2019s\t\nwork.\tEarly\tdiagnosis\tbrings\tquality\tof\tlife\tbenefits\tbecause\tthe\teffects\tof\t\ncancer\tand\tits\ttreatments\tare\tlikely\tto\tbe\tfar\tgreater\tif\tdiagnosed\tlate.\t\nHigh\tquality,\tpersonalised\ttreatment\tin\tspecialised\tcentres\tcan\talso\tbring\t\nbetter\tquality\tof\tlife.\tUp\tuntil\tnow,\tgood\tresearch\tabout\tthe\teffects\tof\t\nprostate\tcancer\tand\tits\ttreatments\ton\tday-to-day\tliving\thas\tbeen\tthin\ton\tthe\t\nground. This means that treatment choices and policy decisions may not \nalways\tbe\tbased\ton\tsound\tevidence.\t\nSo\tin\t2019,\tEuropa\tUomo\tcommissioned\tEurope-wide\tresearch\ton\tthe\t\nquality\tof\tlife\tof\tmen\twith\tprostate\tcancer\t\u2013\tthe\tfirst\ttime\tsuch\tresearch\t\nhas\tbeen\tconducted\tby\tpatients\tthemselves.\tIt\twas\tbased\ton\tan\tonline\t\nsurvey\texploring\texperiences\tof\ttreatment\tand\tlife\tafterwards.\nBased\ton\tnearly\t3,000\tresponses,\tthe\tsurvey\tfindings\tprovide\ta\tnew\nperspective.\tMost\tother\tquality\tof\tlife\tstudies\tare\tconducted\tby\tdoctors\tin\ta\nclinical\tenvironment,\twhen\tpatients\tare\tvisiting\tfor\ttreatment\tor\tcheck-ups.\t\nThe\tEUPROMS\tquestionnaire\twas\tcompleted\tby\tmen\tin\ttheir\town\ttime,\tin\t\nthe\tcomfort\tof\ttheir\thomes,\tmeaning\tthey\thad\tmore\ttime\tto\tconsider\ttheir\t\nanswers\tand\tmight\thave\tfelt\tmore\tat\tease\tto\tsay\thow\tthey\treally\tfeel.\tAbout EUPROMSThe\tfindings\there\tpresent\tan\toverview\tof\twhat\tEUPROMS\tdiscovered,\tand\t\nare\tdesigned\tfor\ta\tgeneral,\trather\tthan\ta\tscientific,\taudience.\t They\tare\ta\t\n\u201csnapshot\u201d\tpicture\tof\twhat\tquality\tof\tlife\tissues\tare\tbeing\texperienced\tby\t\nmen\twith\tprostate\tcancer\tat\ta\tparticular\tpoint\tof\ttime.\t The\tstudy\tcould\t\nnot\tlook\tat\tindividual\trespondents\u2019\tmedical\tcondition\tbefore\ttreatment,\tor\t\nthe\tdetails\tof\thow\tprostate\tcancer\tpatients\tdiffer\tfrom\tthe\tpopulation\tin\t\ngeneral.\t That\twould\thave\tbeen\ta\tdifferent\tkind\tof\tstudy.\t\nThe\tfindings\tprovide\tinformation\tthat\tmay:\n\u2022 help patients and their doctors make decisions about treatments\n\u2022\thelp\tin\tcampaigning\tfor\tearly\tdiagnosis\tof\tprostate\tcancer\tand\t\npromoting\tapproaches\tsuch\tas\tactive\tsurveillance\nYou\tare\twelcome\tto\tpublicise\tthe\tresults\tor\tcharts\twithout\tpermission,\tbut\t\nthey\tmust\talways\tbe\tcredited\tto\tEuropa\tUomo\u2019s\tEUPROMS\tstudy.\t\nAbout the questionnaire\n\u2022\t20-minute\tonline\tsurvey\tfor\tmen\twho\thad\treceived\ttreatment\tfor\tprostate\t\ncancer\n\u2022\tAvailable\tin\t 19\tlanguages\n\u2022\tUsed\tvalidated\tquality-of-life\tquestionnaires:\tEPIC-26\tand\tEORTC-QLQ\t\nand EQ-5D-5L \n\u2022 Responses were anonymous\nEUPROMS (Europa Uomo Patient Reported Outcome Study) 7 6\n EUPROMS (Europa Uomo Patient Reported Outcome Study)Geographical response\nThere\twas\ta\twide\tresponse\tacross\t25\tcountries,\tbut\tthere\twas\tan\tunder-\nrepresentation\tfrom\tEastern\tEurope\tand\tsome\tunder-representation\tfrom\t\nSouthern Europe.\nAbout the respondents\n\u2022\t2943\tresponses\tfrom\t25\tcountries\n\u2022\tAverage\tage:\t70\n\u2022\tAverage\tage \tat\tdiagnosis:\t64\n\u2022\t82%\tlive\twith\ta\tpartner\n\u2022\tMost\thad\thad\tsurgery\tas\tfirst\t\ntreatment \nAs\tyou\twill\tsee\tfrom\tthe\tdistribution\t\ngraph\tof\tage\tat\tfirst\tdiagnosis,\t\nmore\tthan\t50%\tof\trespondents\twere\t\ndiagnosed\tbefore\tthey\twere\t65\t(see\t\npage\t7).\t This\tcounters\tthe\tidea\tthat\t\nprostate\tcancer\tis\ta\tdisease\tof\told\t\nmen.Most\trespondents\twere\tliving\twith\ta\tpartner,\twhich\tis\timportant\tgiven\tthe\t\neffects\tthat\ttreatment\tcan\thave\ton\tsexual\tfunction.\t\nThere\tis\ta\tslight\tbias\tin\trespondent\tprofile\ttowards\ta\thigher\tlevel\tof\t\neducation.Age of respondents Age at diagnosis\nAverage age of respondent:\n70 yearsAverage age at diagnosis:\n64 years4%\n6\n13\n21\n26\n19\n10<55\n55\u201359\n60\u201364\n65\u201369\n70\u201374\n75\u201379\n80+11%\n17\n24\n24\n16\n6\n2\nUniversity entrance\ncertificate\nEntrance certificate for a\nhigher technical college\nComprehensive school\nIntermediate\nsecondary school\nLower secondary\nschool or equivalent\nOther\nNoneLiving situation Education\n14%\nAlone82%\nWith partner\n3%\nWith other\nfamily31%\n28\n13\n11\n7\n8\n1300+Number of\nrespondents\n100\u2013299\n50\u201399\n1\u2013492,943 responses 25 countries\nNorway: 506\nSweden: 386\nBelgium: 339\nGermany: 253\nThe Netherlands: 244\nFrance: 234\nDenmark: 188\nUK: 187\nPoland: 109\nPortugal: 75\nItaly: 71\nAustria: 66\nFinland: 65\nSpain: 55\nLithuania: 52Other (mainly Cyprus): 38\nIreland: 26\nLatvia: 11\nHungary: 10\nEstonia: 8\nSlovak Republic: 8\nSwitzerland: 7\nCzech Republic: 3\nBulgaria: 1\nGreece: 1\nEUPROMS (Europa Uomo Patient Reported Outcome Study) 9 8\n EUPROMS (Europa Uomo Patient Reported Outcome Study)Most\tpatients\thad\tonly\treceived\tone\ttreatment\tup\tto\tthe\tstart\tof\tthe\t\nsurvey.\t\tAbout\t60%\tof\trespondents\thad\treceived\tradical\tprostatectomy,\tso\t\nthe\toverall\tresults\twill\tbe\tinfluenced\tby\tthe\teffects\ton\tquality\tof\tlife\tof\tthat\t\nparticular treatment. About the analysis\nData\twas\tanalysed\t by\tProfessor\tMonique\tRoobol\tand\ther\t team\tat\t\nErasmus\tUniversity\t Medical\tCentre,\tDepartment\t of\tUrology,\tRotterdam.\nSome\tof\tthe\tfindings\there\tare\tbased\ton\traw\tsurvey\tresponses\tand\nstatistical\tsignificance\thas\tnot\tbeen\tcalculated\tor\tdisplayed.\tHowever,\tthe\nfindings\tmay\thelp\tprovide\tvital\tinformation\tfor\tclinical\tdecision-making.\nReporting the study results\nThe\tstudy\tbegan\tin\tAugust\t2019\tand\tthe\tfirst\tresults\twere\treported\tin\t\nJanuary\t2020.\tSince\tthen,\tits\tfindings\thave\tbeen\treported\tand\tdiscussed\t\nwidely,\tfor\texample\tat:\n\u2022\tThe\tEuropean\tAssociation\t of\tUrologists\t(EAU)\tCongress \t2020\n\u2022\tThe\tEAU\tSection\tof\tOncological\tUrology\tannual\tmeeting\n\u2022\tThe\tEuropean\tSociety\tfor\tMedical\tOncology\t(ESMO)\tCongress\n\u2022\tThe\tEuropean\tMultidisciplinary\tCongress\ton\tUrological\tCancers\t(EMUC)\n\u2022\t\t\tA\tEuropean\t Organisation\tfor\tResearch\tand\t Treatment\tof \tCancer\t  \n(EORTC)\twebinar\t\nFindings\thave\talso\tbeen\tpublished\tin\tvarious\tpublications\tincluding\t\nEuropean Urology Focus magazine.\nHow we hope the results will be used\nThe\tEUPROMS\tfindings\tprovide\ta\t\u201csnapshot\u201d\t\npicture\tof\tthe\tquality\tof\tlife\tissues\t\nexperienced by men with prostate cancer \nacross\tEurope\tat\ta\tparticular\tpoint\tof\ttime.\t\nThey\tprovide\tinformation\tthat\tmay\thelp\t\npatients and their doctors make decisions \nabout treatments.\nThey\tmay\talso\thelp\tin\tcampaigning\tfor\tearly\t\ndiagnosis\tof\tprostate\tcancer\tand\tpromoting\t\napproaches\tsuch\tas\tactive\tsurveillance.Three\n300Four\n70\nOne\n1,937Two\n636Most common\nfirst treatments:\n1. Surgery\n2. External beam \nradiotherapy (EBR)\n3. Active surveillance (AS)\nMost common\nsecond treatments:\n1. Surgery and EBR\n2. Androgen deprivation \ntherapy and EBR\n3. AS and surgeryNumber of\ntreatments\nper person\nEUPROMS (Europa Uomo Patient Reported Outcome Study) 11 10\n EUPROMS (Europa Uomo Patient Reported Outcome Study)EUPROMS\tfindings1. General findings about quality of life\nTaken overall, respondents\u2019 quality of life is good. Chart G1 shows all \nthe respondents rating their quality of life from one to seven, and the \npercentage in each category.\nBut\tsome\taspects\tof\tlife\tare\tmuch\tbetter\tthan\tothers.\tChart\tG2\tshows\thow\t\ndifferent\taspects\tof\tquality\tof\tlife\tare\taffected\tafter\ttreatment.\t The\tlower\t\nthe\tscore,\tthe\tlower\tthe\tquality\tof\tlife.\tIt\u2019s\tclear\tthat\tlack\tof\tsexual\tfunction,\t\nand\tto\ta\tlesser\textent\tincontinence,\taffect\tmen\u2019s\tquality\tof\tlife\tmuch\tmore\t\nthan\tother\ttreatment\tafter-effects.\n*EPIC-26 scorer(G2) How does treatment affect quality of life?\n(Quality of life scores*. Lowest score indicates most troublesome effects)\nUrinary incontinence\nBowel effects\nWorse quality of life Better quality of lifeSexual function\n88Hormonal problems 81\nUrinary obstruction 847227Patients\u2019 sex lives \nare affected most \nafter treatment*EORTC-QLQ-C30Very poor Excellent\n1%\n3.58\n9.819.7\n35.922.1(G1) Quality of life during the past week\nVery poor to excellent (% of all respondents)\nMen surveyed in EUPROMS1 2 3 4 5 6 7\n13\n EUPROMS (Europa Uomo Patient Reported Outcome Study) 12EUPROMS\t(Europa\tUomo\tPatient\tReported\tOutcome\tStudy)\t2.  Findings about discomfort, tiredness  \nand insomnia\nLooking at specific aspects of quality of life after prostate cancer \ntreatment, when it comes to pain and discomfort, this increases as \nmen move through the treatment stages. More than three times the \npain and discomfort are reported after chemotherapy compared \nwith early stage treatments (D1).For\ttiredness,\tmore\tthan\tone\tthird\tof\tmen\twho\thad\treceived\tchemotherapy\t\nsaid\tthey\thad\tfelt\ttired\tin\tthe\tpast\tweek\t\u2013\ttwice\tthe\tnumber\tof\tother\t\ntreatment\tgroups\t(D2).\t\nAnd\twith\tinsomnia,\tthe\tstudy\tfound\tmen\twere\taffected\tmore\tafter\t\nradiotherapy\twith\tADT \tand\talso\tafter\tchemotherapy\t(D3).\t The\teffects\tnearly\t\ndouble as treatment progresses.\n*EQ-5D-5L questionnaire(D1) Which treatments are linked with pain or discomfort?\n(% of respondents saying they were in moderate, severe\nor extreme pain/discomfort at time of survey*)\nActive surveillance\nRadical prostatectomy\nRadiotherapy\nRadiotherapy and ADT\nChemotherapy7.5\n10.4\n14.3\n34.17.9% Men who have received \nradiotherapy plus ADT and \nchemotherapy experience \nmore discomfort than other \ntreatment groups*EORTC-QLQ-C30(D2) Which treatments are linked with tiredness?\n(Respondents who said they have been quite or very tired in the past week*)\nActive surveillance\nRadical prostatectomy\nRadiotherapy\nRadiotherapy and ADT\nChemotherapy11.9\n16.8\n15.7\n36.613.4%\nMore than a third of \nmen who have \nreceived chemotherapy \nsay they feel tired \n*EORTC-QLQ-C30Men who have received \nradiotherapy plus ADT \nand chemotherapy \nexperience more \ninsomnia than other \ntreatment groups(D3) Which treatments are linked with insomnia?\n(Respondents who said that have had 'quite a bit'\nor 'very much' trouble sleeping in the past week*)\nActive surveillance\nRadical prostatectomy\nRadiotherapy\nRadiotherapy and ADT\nChemotherapy13.7\n16.1\n24.6\n28.914%\n15\n EUPROMS (Europa Uomo Patient Reported Outcome Study) 14EUPROMS\t(Europa\tUomo\tPatient\tReported\tOutcome\tStudy)\t3. Findings about mental health\nThe study found that men experience roughly equal levels of anxiety \nin the first and second line of treatment, and anxiety and depression \ntend to diminish after treatment ends (M1). \n1 238 36\n59%66\n24\n827\n10\n437\n20\n735\n18\n8Second line of\ntherapy or laterFirst line\nof therapyOn active\nsurveillancePreviously, but not\ncurrently, receiving\ntreatment\nMen experience roughly equal levels of \nanxiety in first and second line treatment(M1) How depressed/anxious are men at different stages\nof treatment?\nNot Slightly Moderately Severely Extremely\nBut\ta\trecurrence\tcan\taffect\t\nmental health a great deal. More \nthan\thalf\tof\tthe\trespondents\t\nwho had a recurrence rate the \neffect\ton\ttheir\tmental\thealth\tas\t\nsix\tor\tmore\ton\ta\tscale\tof\tone\t\nto\tten\t\u2013\tin\tother\twords,\tit\thad\ta\t\nsignificant\teffect\t(M2).\nThe\tstudy\tfound\tthat\t42%\tof\t\nmen\twho\thave\tbeen\ttreated\tfor\t\nprostate cancer say they are \nanxious or depressed to some \nextent\t(M3,\tpage\t16).Not at all ExtremelyMore than half of men \nwith a recurrence gave \na score of six or more(Respondents who had a cancer recurrence on a rating scale of 1 to 10) \n1 2 3 4 5 6 7 8 9 10(M2) How much does a recurrence of prostate cancer affect\nmental health?\n671615\n1014\n8 8 8 8%\nEUPROMS (Europa Uomo Patient Reported Outcome Study) 16 17 \t EUPROMS\t(Europa\tUomo\tPatient\tReported\tOutcome\tStudy)Which treatments are most linked with mental health problems? Chart M4 \nshows\tthat\tthe\tproblems\tseem\tto\tget\tworse\tthe\tmore\tadvanced\tthe\tcancer,\t\nwhen\tmen\tare\tmore\tlikely\tto\tbe\treceiving\tADT \tand\tchemotherapy.\t\nActive\tsurveillance\tseems\tto\tbe\tassociated\twith\thigher\tlevels\tof\tdepression\t\nor anxiety than treatments such as radical prostatectomy and radiotherapy. \nThis may be related to the long-term worry that can be brought by regular \ntesting,\tand\tthe\tfact\tthat\ttreatment\tdecisions\tmay\tstill\thave\tto\tbe\tmade.\t\n(% of respondents saying they were moderately, severely\nor extremely depressed or anxious at time of survey*)(M4) Which treatments are linked with mental health problems?\nActive surveillance\nRadical prostatectomy\nRadiotherapy\nRadiotherapy and ADT\nChemotherapy 27.618.31311.815.1%Men who have \nreceived \nradiotherapy plus \nADT and \nchemotherapy \nexperience more \ndepression and \nanxiety than other \ntreatment groups\n*EQ-5D-5L questionnaire\n4. Findings about sexual function\nWhen it comes to sexual function after treatment, the study indicated \nthat quality of life is better after prostatectomy than radiotherapy \n(S1). This may be surprising, given the risks of nerve damage \nduring surgery. But the difference between radiotherapy and radical \nprostatectomy is small and may not be clinically relevant. Slightly\n27.7%(At time of survey*)(M3) What proportion\nof men who have been\ntreated for prostate\ncancer are anxious\nor depressed?Extremely\n0.5%\nSeverely\n3.7%\nModerately\n10.8%Not at all\n57.4%\n42% of men say they are \nanxious or depressed to \nsome extent\n*EQ-5D-5L questionnaire\n*EPIC-26 scores Worse quality of life Better quality of life17\nActive surveillanceActive surveillance \u2013\nradical prostatectomyRadical prostatectomyRadical prostatectomy \u2013\nradiotherapy\nRadiotherapy\nRadiotherapy\u2013Androgen\ndeprivation therapyChemotherapy(Quality of life scores*. Lowest score indicates worst effects)(S1) How is sexual function after different treatments?\nRadiotherapy is related \nto worse quality of life \nthan prostatectomy\n57262115\n1812EUPROMS (Europa Uomo Patient Reported Outcome Study) 19 18\n EUPROMS (Europa Uomo Patient Reported Outcome Study)Looking\tat\thow\tdifferent\t treatments\taffect\t sexual\tfunctioning\t (S4,\tsee\tpage\t\n20),\tmore\tthan\thalf\tof\tmen\twho\t have\thad\ta\tprostatectomy\tfind\t that\tsexual \t\nfunctioning\t is\ta\tbig\tor\tmoderate\tproblem\t for\tthem.\tSexual\tfunctioning\tseems \t\nto\tbe\ta\tless\tsignificant\tproblem\t after\tradiotherapy:\t 44.5%\tfor\tradiotherapy \t\nhad\tsignificant\tproblems\t compared\twith\t54.5%\tfor\tprostatectomy. \tQuality\tof\tlife\tscores\tfor\tboth\ttreatments\tare\tobviously\tlow\tcompared\twith\t\nactive\tsurveillance.\tComparing\tthese\tfigures\tto\tthe\tgeneral\tpopulation,\tthe\t\naverage\tEPIC\tsexual\tfunction\tscore\tfor\tmen\twithout\tprostate\tcancer\tis\t\n55.8,\twhich\tis\tclearly\tvery\tsimilar\tto\tthe\tactive\tsurveillance\tscore\there.\t\t\nHow\tbig\ta\tproblem\tis\tsexual\tfunctioning\tafter\ttreatment?\tChart\tS2\tshows\tit\t\nis\ta\tbig\tor\tmoderate\tproblem\tin\taround\thalf\tof\tmen.\t\nWhen\tasked\thow\tthey\trated\ttheir\tability\tto\tfunction\tsexually,\taround\tthree\t\nquarters\tof\tmen\twith\tprostate\tcancer\trated\tit\tas\tpoor\tor\tvery\tpoor\t(S3).\t\nFor\tcomparison,\tit\tis\tinteresting\tto\tlook\tat\ta\t2017\tstudy\tof\tmen\tof\tslightly\t\nolder\tage\t(average\tage\t74.5)\twho\tdid\tnot\thave\tprostate\tcancer,\twhich\tused\t\nthe\tsame\tEPIC-26\tmeasures\t(Venderbos\tet\tal,\tPMID:\t28168601).\tIt\tfound\t\nthat\t50%\tof\tthese\tmen\trated\ttheir\tability\tto\tfunction\tsexually\tas\tpoor\tor\tvery\t\npoor.\tClearly,\tthis\tis\ta\tsignificantly\tlower\tpercentage\tthan\tthe\t76%\tof\tmen\t\nwith prostate cancer in our study.\n*EPIC-26 scoresVery poor\n56%Very\ngood\n2%\nPoor\n20%Fair\n14%Good\n8%(S3) How do men rate their current ability to function sexually\nafter treatment?\n(All respondents*)\nThree in four men who have been treated \nfor prostate cancer rate their current ability \nto function sexually as poor or very poor.\n*EPIC-26 scoresBig\nproblem\n28%No\nproblem\n17%\nModerate\nproblem\n22%Small\nproblem\n18%Very small\nproblem\n15%(S2) How big a problem is sexual functioning?\n(All respondents*)\nHalf of all men \nresponding said that \nsexual function has \nbeen a moderate or \nbig problem after \ntreatmentEUPROMS (Europa Uomo Patient Reported Outcome Study) 20 21 \t EUPROMS\t(Europa\tUomo\tPatient\tReported\tOutcome\tStudy)This\tis\ta\tclearer\t finding\tthan\twe\tsaw\t in\tchart\tS1,\twhere\tsexual\tfunction \t\nvalues\twere\t quite\tsimilar\t between\tradiotherapy\tand\t prostatectomy.\tBut\t both\t\nfindings\tindicate\tthat,\twhen\tit\tcomes\t to\tsexual\tfunction,\t the\ttwo\tmajor\tfirst \t\ntreatments\t for\tprostate\tcancer\t have\tan\timportant\t effect\ton\t quality\tof\tlife.\nOnly\t34%\tof\tmen\thave\ttried\tmedications\tand\tdevices\tto\timprove\terections,\t\nso\tthere\u2019s\tclearly\ta\tneed\tto\tgive\tmen\tmore\tadvice\ton\tthese\tapproaches\tto\t\nhelp\tovercome\tany\tproblems\t(S5).5. Findings about urinary incontinence\nLooking at incontinence, prostatectomy is related to lower quality of \nlife than radiotherapy. Other treatments show fewer effects (U1).*EPIC-26 scores(Prostatectomy patients only*)(S4) How big a problem is lack of sexual functioning after surgery? \nMore than half of prostatectomy patients say lack \nof sexual function is a significant problem to them.54.5%33%12.5 %\nBig problem or\nmoderate problemSmall or very\nsmall problemNo problem\n(Radiotherapy patients only*)How big a problem is sexual functioning after radiotherapy? \n44.5 %40%15%\nBig problem or\nmoderate problemSmall or very\nsmall problemNo problem\n(All survey respondents)  (S5) How many prostate cancer patients have tried\nmedications and devices to improve erections?\nNo\n66%Yes\n34%\n*EPIC-26 scores Worse quality of life Better quality of life100\n10071\n73\nActive surveillanceActive surveillance \u2013\nradical prostatectomy\nRadical prostatectomy\nRadical prostatectomy \u2013\nradiotherapy\nRadiotherapy\nRadiotherapy\u2013Androgen\ndeprivation therapyChemotherapy(Quality of life scores*. Lowest score indicates worst effects)(U1) How is continence after different treatments?\nProstatectomy \nis related to \nworse quality \nof life than \nradiotherapy65\n9286\nEUPROMS (Europa Uomo Patient Reported Outcome Study) 23 22\n EUPROMS (Europa Uomo Patient Reported Outcome Study)Overall,\t61%\tof\tthe\tmen\tsurveyed\tsaid\tthey\tlacked\tsome\turinary\tcontrol\t\n(frequent\t dripping\t or\tno\tcontrol)\t(U2).\tThose\twho\thave\t had\ta\tprostatectomy\t\nreport\tless\turinary\tcontrol\tthan\tthose\twho\thave\thad\tradiotherapy\tor\tother\t\ntreatments,\tand\tthis\tresults\tin\ta\tlower\tquality\tof\tlife\trelated\tto\turinary\t\nsymptoms.\tComparing\tthe\tsurgery\tfigure\twith\tactive\tsurveillance\tsuggests\t\nthat\tsurgery\tdoubles\tthe\trate\tof\tincontinence.\nWhat\tdoes\tthis\tmean\tfor\tpatients\tin\tpractical\tterms?\t The\tsurvey\tasked\tmen\t\nhow\tmany\tincontinence\tpads\tthey\tuse\teach\tday,\tand\tacross\tall\tthe\tsurvey\t\nrespondents\tover\ta\tthird\tuse\tone\tor\tmore\tpads\ta\tday\t(U3).\tOf\trespondents\t\nwho\thad\thad\ta\tprostatectomy,\thalf\twere\tusing\tpads.\t To\tput\tthis\tinto\t\ncontext,\ta\t2017\tstudy\tof\tmen\twith\troughly\tthe\tsame\tage\tprofile\twho\thad\t\nNOT\tbeen\ttreated\tfor\tprostate\tcancer\tfound\tthat\taround\t10%\twear\tpads\t\n(PMID:\t28168601).\tSo\tthere\tis\tclearly\ta\tsignificant\teffect\there.\nThe\tsurvey\tfound\tthat\t17%\tof\tmen\tjudged\tdripping\tand\tleakage\tto\tbe\ta\tbig\t\nor\tmoderate\tproblem\t(U4,\tsee\tpage\t24).\tAnd\tif\tyou\tbreak\tdown\tthis\tfigure\t\ninto\tthose\twho\thave\treceived\tprostatectomy\tand\tradiotherapy,\ttreatment\t*EPIC-26 scoresAfter radiotherapy\nplus ADTDuring active\nsurveillance\nAfter radiotherapy\naloneAfter surgery plus\nradiotherapyAfter surgery alone(Proportion of all men surveyed with frequent dripping or no control*)(U2) What proportion of men lack urinary control after\ntreatment?\n61% of men treated say \nthey lack some urinary \ncontrol (occasional \ndribbling to complete \nlack of control)18.2%\n17.9\n10.6\n9.9\n7.2\n*EPIC-26 scores(All survey respondents*)(U3) How many pads do men who have been treated \nusually use?\n37% of men use one \nor more incontinence \npads every day after \ntreatment7% 62.5%None\n22%One\na day\n8.5%Two\na dayThree\nor more\nEUPROMS (Europa Uomo Patient Reported Outcome Study) 25 24\n EUPROMS (Europa Uomo Patient Reported Outcome Study)received\tis\ta\tclear\tinfluence\ton\tthis\tproblem.\tFor\tprostatectomy\tpatients\t\n67%\tsay\tdripping\tand\tleakage\tis\ta\tproblem.\tWhile\t48%\tof\tradiotherapy\t\npatients\tsay\tthat\tdripping\tand\tleakage\tis\ta\tproblem\t(U5).\t\nKey messages  \nfrom\tEUPROMS\n*EPIC-26 scores(Prostatectomy patients only*)(U5) How big a problem is dripping and leakage after surgery?\n67% of prostatectomy patients say dripping and leakage is a problem20%47%33%\nBig problem or\nmoderate problemSmall or very\nsmall problemNo problem\n(Radiotherapy patients only*)How big a problem is dripping and leakage after radiotherapy?\n9%39%52%\nBig problem or\nmoderate problemSmall or very\nsmall problemNo problem*EPIC-26 scores(All survey respondents*) (U4) How big a problem is dripping and leakage?\n17%41%42%\nBig problem or\nmoderate problemSmall or very\nsmall problemNo problem\n58% of men who have been treated for prostate \ncancer say dripping and leakage is a problem\n*EPIC-26 scores(Prostatectomy patients only*)(U5) How big a problem is dripping and leakage after surgery?\n67% of prostatectomy patients say dripping and leakage is a problem20%47%33%\nBig problem or\nmoderate problemSmall or very\nsmall problemNo problem\n(Radiotherapy patients only*)How big a problem is dripping and leakage after radiotherapy?\n9%39%52%\nBig problem or\nmoderate problemSmall or very\nsmall problemNo problemEUPROMS (Europa Uomo Patient Reported Outcome Study) 27 26\n EUPROMS (Europa Uomo Patient Reported Outcome Study)There are three main take-home messages from the EUPROMS findings.\nThe\tfirst\tis\tthat\tactive\tsurveillance\tshould\tbe\talways\tbe\tconsidered,\t\nbecause\toverall\tit\tbest\tprotects\tquality\tof\tlife.\t The\tcontrast\tbetween\t\nactive\tsurveillance\tand\tother\tapproaches\tis\tparticularly\tclear\tin\tterms\tof\t\nincontinence\tand\tsexual\tfunction.2. Early detection is key\nActive surveillance\nRadical prostatectomy\nRadiotherapy\nRadiotherapy\u2013Androgen\ndeprivation therapy\nChemotherapy\n0 5 10 15 20 25 30 35 40Discomfort Tiredness Insomnia Mental health(% of patients with moderate, severe and very severe problems)\nThe\tsecond\tmessage\tis\tthat\tearly\tdetection\tof\tprostate\tcancer\tis\tof\tthe\t\nutmost\timportance.\t The\tmore\tadvanced\tthe\tprostate\tcancer\tat\tdiagnosis,\t\nthe\tworse\tthe\teffects\tof\ttreatment\ton\tquality\tof\tlife.\t The\tresearch\tclearly\t\nshows\tthat\tmany\tsymptoms\tthat\taffect\tquality\tof\tlife\tare\texperienced\tmore\t\nseverely\twith\ttreatments\tassociated\twith\tmore\tadvanced\tprostate\tcancer.\t\nFinally,\thigh\tquality\ttreatment\tand\tsupport\tare\tessential.\t The\tEUPROMS\t\nresults\tshow\tthe\tsevere\teffects\tthat\tcan\tcome\twith\ttreatment\tfor\tprostate\t\ncancer. Men need all the expertise and experience they can get during \ntreatment\tand\tafter,\twith\tinformation\tand\tsupport\tat\teach\tstage\tof\tthe\t\njourney.\tEvery\tman\twith\tprostate\tcancer\tshould\tbe\ttreated\tin\ta\tcancer\t\ncentre with multidisciplinary teams.\n1. Active surveillance should be considered as the\nfirst treatment in order to ensure the best quality of life\nIncontinence Average EPIC score Sexual function Average EPIC score\nActive surveillance\nRadical prostatectomyRadiotherapyRadiotherapy\u2013Androgen\ndeprivation therapy\nChemotherapy100\n57\n2118\n1712100\n92\n86\n73EUPROMS (Europa Uomo Patient Reported Outcome Study) 29 28\n EUPROMS (Europa Uomo Patient Reported Outcome Study)Further\tinformation\nThe quality of life measures used\nThe\tsurvey\tquestions\twere\tcomposed,\tand\ttheir\tresponses\tanalysed,\ton\tthe\t\nbasis\tof\tthree\tvalidated\tmeasures\tused\twidely\tin\tEurope\tto\tevaluate\tpatient\t\nquality\tof\tlife.\t\t They\tare:\t\nEQ-5D-5L\t\u2013\tused\tto\tevaluate\tgeneric\thealth\tstatus\nEORTC-QLQ-C30\t\u2013\tused\tto\tevaluate\tquality\tof\tlife\trelated\tto\tcancer\nEPIC-26\t\u2013\tused\tto\tevaluate\tquality\tof\tlife\trelated\tto\tprostate\tcancer\t\nspecifically\nThe\tfindings\tpresented\tin\tthis\tpaper\tsummarise\tsome\tof\tthe\tdetailed\t\nfindings\tarising\tfrom\tEUPROMS,\tusing\tthese\tmeasures.\nImpact of EUPROMS\nSince\tearly\t2020,\tthe\tEUPROMS\tfindings\thave\tbeen\twidely\treported\tat\t\nconferences,\tin\tjournals,\tat\tconferences\tand\twebinars.\t The\tpublication\tof\t\nthe\tEuropean\tCommission\u2019s\tBeating\tCancer\tplan\thas\tmade\tthe\tfindings\t\neven\tmore\tpertinent.\t The\tplan,\tpublished\tin\tFebruary\t2021,\traises\tthe\t\nprospect\tof\tprostate\tcancer\tearly\tdetection\tprogrammes\tthroughout\t\nEurope.\tEuropa\tUomo\thas\tbeen\tcampaigning\tvigorously\tfor\tsuch\tmeasures,\t\npointing\tEuropean\tpoliticians\ttowards\tthe\tfindings\tof\tthe\tEUPROMS\tstudy.\nEarly\tdetection\tclearly\taffects\tquality\tof\tlife.\tEUPROMS\tfound\tthat\tquality\t\nof\tlife\tscores\tare\tbest\tin\tpatients\twhere\tthe\tcancer\tis\tdiscovered\tin\tan\t\nearly,\tcurable\tstage.\tSo\tefforts\ttoward\tearly\tdetection\tand\tawareness\tare\t\nessential\tto\tavoid\tunnecessary\tdeterioration\tof\tquality\tof\tlife.\nThe\tEUPROMS\tquality\tof\tlife\tstudy\tsubstantially\tcontributed\tto\tthe\tinclusion\t\nof\tprostate\tcancer\tearly\tdetection\tin\tthe\tBeating\tCancer\tplan,\tso\tspecial\t\nthanks\tmust\tgo\tto\tall\tthe\tpatients\twho\ttook\ttime\tto\tanswer\tthe\tsurvey:\ttheir\t\nefforts\thave\tmade\ta\tdifference.What happens next?\nCampaigning\tand\tinformation\twork\tneeds\tto\tcontinue,\tto\tprovide\tevidence\t\nsupporting\tthe\tneed\tfor\tearly\tdetection,\tawareness\tand\ttreatment\tand\tcare\t\nimprovements.\t That\tis\twhy\tEuropa\tUomo\tis\tnow\tplanning\ta\tfollow-up\tto\t\nEUPROMS\tstudy\tto\tstrengthen\tthe\tresearch\tbase\tand\tfill\tpossible\tgaps.\t\nAt\ttime\tof\twriting\tthis\tbooket,\tthe\tEUPROMS\t2\tquestionnaire\twas\tbeing\t\nprepared.\nEUPROMS (Europa Uomo Patient Reported Outcome Study) 31 30\n EUPROMS (Europa Uomo Patient Reported Outcome Study)Links\nEuropa\tUomo\towes\ta\thuge\tdebt\tof\tthanks\tto\tthose\twho\thave\tsupported\t\nEUPROMS,\tin\tmany\tdifferent\tways.\nThey\tinclude:\n\u2022  Professor\tMonique\tRoobol,\tLionne\tVenderbos\tand\tSebastian\tRemmers\t\nfrom\tthe\tDepartment\tof\tUrology\tat\tErasmus\tMC,\tRotterdam\n\u2022 The\tEuropean\tAssociation\tof\tUrology\n\u2022 Our\tEUPROMS\tsponsors:\tBayer,\tIpsen\tand\tJanssen\nParticular\tthanks\tgo\tto\tevery\tone\tof\t\nthe\t2,943\tpeople\twho\tresponded\tto\t\nthe EUPROMS questionnaire.\nCredits\nThis\tbooklet\twas\tcompiled\tby:\nSimon\tCrompton,\tediting\tand\twriting\nWesley\tFernandes,\tgraphics\nHils\tTranter,\tdesign\n\u00a9 Europa Uomo 2021You\tcan\tfind\tout\tmore\tabout\tthe\tEUPROMS\tstudy\tby\tfollowing\tthe\tlinks\t\nbelow:\nPowerPoints and summaries\nEarly presentation of findings  by Europa Uomo Chairman Andr\u00e9 \nDeschamps,\tJanuary\t2020\nMain findings presented to the European Association of Urology \t(EAU)\tby\t\nAndr\u00e9\tDeschamps,\tJuly\t2020\nNew findings on mental health \tfrom\tEUPROMS\tannounced,\tNovember\t\n2020\nNew accessible presentation \tof\tresults\tlaunched,\tNovember\t2020\nAccessible presentation available in 17 languages\nJournal papers and conference reports\nPresentation at EAU ,\tJuly\t2020\nPresentation at EMUC \t(Multidisciplinary\tCongress\ton\tUrological\tCancers),\t\nNovember\t2020\nPaper on chemotherapy effects \tin\tAnnals\tof\tOncology,\tSeptember\t2020\nPaper in European Urology Focus \tpresenting\tEUPROMS\tresults,\t  \nDecember 2020\n\" Particular thanks go to every \none of the 2,943 people who \nresponded to the EUPROMS \nquestionnaire. \"AcknowledgementsEUPROMS (Europa Uomo Patient Reported Outcome Study) 32\nwww.europa-uomo.orgEuropa Uomo Central Office\nTel +32 3 644 17 89\neuropauomo@skynet.be\nwww.facebook.com/EuropaUomo  \nhttps://twitter.com/europa_uomo", "metaData": {"source": "EUPROMS Summary of Findings\nBooklet summarising the results of Europa Uomo's quality of life after prostate cancer treatment study Download:\nhttps://www.europa-uomo.org/wp-content/uploads/2021/07/EU_booklet_5July_web.pdf"}}